z-logo
open-access-imgOpen Access
Pre‐ and post‐conditioning with poly I:C exerts neuroprotective effect against cerebral ischemia injury in animal models: A systematic review and meta‐analysis
Author(s) -
Khan Zeeshan Ahmad,
Sumsuzzman Dewan Md.,
Choi Jeonghyun,
Kamenos George,
Hong Yonggeun
Publication year - 2022
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/cns.13851
Subject(s) - neuroprotection , tlr3 , agonist , pharmacology , tumor necrosis factor alpha , tlr4 , medicine , ischemia , receptor , toll like receptor , innate immune system
Background Toll‐like receptor (TLR) agonist polyinosinic–polycytidylic acid (poly I:C) exerts neuroprotective effects against cerebral ischemia (CI), but concrete evidence supporting its exact mechanism of action is unclear. Methods We evaluated the neuroprotective role of poly I:C by assessing CI indicators such as brain infarct volume (BIV), neurological deficit score (N.S.), and signaling pathway proteins. Moreover, we performed a narrative review to illustrate the mechanism of action of TLRs and their role in CI. Our search identified 164 articles and 10 met the inclusion criterion. Results Poly I:C reduces BIV and N.S. ( p  = 0.00 and p  = 0.03). Interestingly, both pre‐ and post‐conditioning decrease BIV (preC p  = 0.04 and postC p  = 0.00) and N.S. (preC p  = 0.03 and postC p  = 0.00). Furthermore, poly I:C upregulates TLR3 [SMD = 0.64; CIs (0.56, 0.72); p  = 0.00], downregulates nuclear factor‐κB (NF‐κB) [SMD = −1.78; CIs (−2.67, −0.88); p  = 0.0)], and tumor necrosis factor alpha (TNF‐α) [SMD = −16.83; CIs (−22.63, −11.02); p  = 0.00]. Conclusion We showed that poly I:C is neuroprotective and acts via the TLR3/NF‐κB/TNF‐α pathway. Our review indicated that suppressing TLR 2/4 may illicit neuroprotection against CI. Further research on simultaneous activation of TLR3 with poly I:C and suppression of TLR 2/4 might open new vistas for the development of therapeutics against CI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here